Phase 3Active, not recruiting
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 1,835 enrolled
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- Zibotentan/Dapagliflozin; Dapagliflozin
- Ages
- adults, older adults
- Registry
- NCT06087835, CTIS2023-504124-26-00
Full record on ClinicalTrials.gov
From the registry
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
Primary outcomes
- Change in eGFR from baseline
History
Primary completion expected
Last registry update
Started
Registered
Papers citing this trial
- Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association